查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087724

治療性卡介苗市場：按疫苗類型、適應症、給藥途徑、治療方案和最終用戶分類的全球市場預測 – 2026–2032 年

Therapeutic BCG Vaccine Market by Vaccine Type, Indication, Route of Administration, Treatment Regimen, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療性 BCG 疫苗市場將成長至 5.1115 億美元，複合年成長率為 5.29%。

主要市場統計數據
基準年 2025 3.5629億美元
預計年份：2026年 3.7449億美元
預測年份 2032 5.1115億美元
複合年成長率 (%) 5.29%

治療性卡介苗仍是高風險非肌肉層浸潤性膀胱癌（NMIBC）的主要輔助免疫療法，尤其適用於原位癌和切除術的高級別Ta/T1期病變。與用於預防結核病的預防性卡介苗不同，治療性卡介苗透過膀胱內灌注給藥，以刺激局部免疫反應對抗惡性尿路上皮細胞。

臨床需求持續存在，且具有重要的流行病學意義。根據國際癌症研究機構 (IARC) 2022 年全球癌症風險評估報告 (GLOBOCAN 2022) 的估計，全球每年約有 61.4 萬例膀胱癌新發病例，超過 22 萬人死於膀胱癌，發病率主要集中在老年人群，且男性發病率顯著高於女性。對於製藥和生物技術生產商而言，治療性卡介苗的市場趨勢取決於對卡介苗供應可靠性、最佳化菌株、改進給藥方案以及針對卡介苗無效疾病的循證替代療法的持續需求。

治療性卡介苗領域發生的變革性變化

目前，治療性卡介苗接種的現狀正受到三個已證實因素的影響：全球卡介苗供應緊張、對卡介苗無反應的非肌肉浸潤性膀胱癌（NMIBC）的臨床定義更加嚴格，以及膀胱保留療法創新技術的快速發展。儘管主要的泌尿系統指南仍然推薦卡介苗作為合格的高風險NMIBC患者的誘導和維持治療，但供不應求正在促使人們重新評估劑量優先級、採用劑量減重方案，並在特定病例中增加膀胱內化療的使用。

人工智慧（AI）的累積影響

人工智慧正開始對治療性卡介苗（BCG）疫苗研發和商業化的累積階段產生影響，涵蓋從藥物發現和生產到臨床運作和藥物安全監測的各個環節。在研發領域，機器學習可用於支持生物標記發現、免疫反應分析、患者分層以及臨床試驗參與者的選擇，這些試驗旨在比較對BCG有反應和無反應的非肌肉層浸潤性膀胱癌（NMIBC）患者群體。

關鍵區域洞察

亞太地區蘊藏著巨大的長期發展機遇，尤其是在中國、印度、日本、韓國和澳大利亞，這主要得益於大規模的老齡人口、不斷完善的泌尿系統基礎設施以及日益成長的癌症診療服務。中國和日本尤其重要，因為兩國膀胱癌患者數量龐大，且擁有完善的醫院癌症診療體系；印度則透過擴大癌症診療體系和提高公共醫療保險覆蓋率來改善癌症診療服務。韓國和澳洲擁有先進的診斷能力、完善的泌尿系統網路以及嚴格的品質和安全監管要求。

關鍵群體特定見解

東協市場為治療性卡介苗生產商提供了切實可行的成長路徑，這主要得益於新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國癌症中心診斷和泌尿系統腫瘤服務的擴展。在整個東協市場取得商業性成功，取決於低溫運輸的可靠性、臨床醫生的培訓、醫院參與競標的機會以及能夠保障產品穩定供應的公私合營合作採購模式。

主要國家的概況

美國是一個至關重要的市場，這得益於其較高的指南普及率、強大的泌尿系統學術網路、廣泛的膀胱鏡檢查以及針對卡介苗無效的非肌肉層浸潤性膀胱癌（NMIBC）替代療法的完善監管管道。加拿大採用類似的臨床標準，但其報銷模式因省份而異，醫療技術評估也較為集中。墨西哥和巴西人口眾多，癌症治療需求不斷成長，因此具有成長潛力，但公立和私立醫療系統之間的可及性存在差異，且不同地區的專科醫生數量也存在差異。

為行業領導者提供的實用建議

產業領導者應優先考慮生產冗餘、檢驗的菌株管理以及地理分散的供應鏈，以降低因卡介苗反覆供不應求而面臨的風險。企業也應投資於真實世界數據（REW）項目，以衡量無復發生存期、疾病進展、不利事件、治療完成率、再治療模式以及減重方案後的療效。

調查方法

本執行摘要基於對已核實的公共資源和監管資訊的二手研究，包括國際癌症研究機構全球癌症研究網路（IARC GLOBOCAN）的癌症統計數據、世界衛生組織（WHO）和各國癌症相關資訊來源、泌尿系統指南制定機構、法規核准資料庫、同行檢驗的腫瘤學文獻以及已建立的臨床試驗註冊庫。本分析重點在於卡介苗（BCG）在非肌肉層浸潤性膀胱癌（NMIBC）的治療應用，並將其與結核病疫苗接種區分開來。

結論

由於卡介苗（BCG）疫苗在膀胱癌治療中應用數十年，且其對高危險非肌肉層浸潤性膀胱癌（NMIBC）的療效已獲得指引支持，因此卡介苗在膀胱癌治療中仍扮演重要角色。然而，供應限制、治療流程的不斷演變以及人們對卡介苗抗藥性疾病日益成長的擔憂，正在重新定義卡介苗的競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 治療性卡介苗市場：依疫苗類型分類

  • 標準卡介苗
  • 改良型卡介苗
  • 下一代基於卡介苗的免疫療法

第8章 治療性卡介苗市場：依適應症分類

  • 非肌肉層浸潤性膀胱癌
  • 結核
  • 自體免疫疾病與感染疾病

第9章 治療性卡介苗市場：依給藥途徑分類

  • 膀胱內給藥
  • 皮內給藥
  • 靜脈

第10章 治療性卡介苗市場：依治療方案分類

  • 誘導治療
  • 維持治療
  • 聯合治療方案

第11章 治療性卡介苗市場：依最終用戶分類

  • 醫院
  • 腫瘤中心
  • 專科診所
  • 研究機構

第12章 治療性卡介苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 治療性卡介苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 治療性卡介苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AJ Vaccines A/S
  • Bharat Biotech International Limited
  • Biofabri
  • BioFarma
  • Biological E. Limited
  • Biomed Lublin SA
  • Bul Bio-NCIPD Ltd.
  • China National Biotec Group
  • GlaxoSmithKline plc
  • GreenSignal Bio Pharma Ltd.
  • ImmunityBio, Inc.
  • Indian Immunologicals Limited
  • Instituto Butantan
  • InterVax Ltd.
  • Japan BCG Laboratory
  • Laboratorios Reig Jofre SA
  • Merck & Co., Inc.
  • Microgen（NPO Microgen）
  • Panacea Biotec Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Statens Serum Institut
  • Taj Pharmaceuticals Limited
  • Torlak Institute of Virology
Product Code: MRR-030298DFF712

The Therapeutic BCG Vaccine Market is projected to grow by USD 511.15 million at a CAGR of 5.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 356.29 million
Estimated Year [2026] USD 374.49 million
Forecast Year [2032] USD 511.15 million
CAGR (%) 5.29%

Therapeutic BCG vaccine remains the backbone of adjuvant immunotherapy for high-risk non-muscle-invasive bladder cancer (NMIBC), particularly carcinoma in situ and high-grade Ta/T1 disease following transurethral resection of bladder tumor. Unlike prophylactic BCG used for tuberculosis prevention, therapeutic BCG is administered intravesically to stimulate localized immune activity against malignant urothelial cells.

The demand foundation is clinically durable and epidemiologically significant. IARC GLOBOCAN 2022 estimated approximately 614,000 new bladder cancer cases and more than 220,000 bladder cancer deaths worldwide, with incidence concentrated among older adults and substantially higher in men. For pharmaceutical and biotechnology manufacturers, the therapeutic BCG vaccine landscape is shaped by persistent need for BCG supply reliability, optimized strains, improved administration schedules, and evidence-based alternatives for BCG-unresponsive disease.

Transformative Shifts in the Therapeutic BCG Landscape

The therapeutic BCG vaccine landscape is being reshaped by three verified forces: global BCG supply constraints, stricter clinical definitions of BCG-unresponsive NMIBC, and rapid expansion of bladder-sparing treatment innovation. Major urology guidelines continue to recommend induction and maintenance BCG for eligible high-risk NMIBC, but shortages have led to dose prioritization, reduced-dose protocols, and greater use of intravesical chemotherapy in selected cases.

For manufacturers, this creates a dual opportunity. Established producers can strengthen competitive positioning through resilient biologics manufacturing, strain consistency, cold-chain excellence, and regulatory-grade quality systems. Emerging developers can compete through recombinant BCG platforms, immune-enhancing combinations, and next-generation intravesical therapies designed to address recurrence, tolerability, and progression risk.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to affect the cumulative economics of therapeutic BCG vaccine development and commercialization across discovery, manufacturing, clinical operations, and pharmacovigilance. In research and development, machine learning can support biomarker discovery, immune-response profiling, patient stratification, and trial enrichment for BCG-responsive versus BCG-unresponsive NMIBC populations.

In manufacturing, AI-enabled process analytics can improve batch monitoring for live biotherapeutic products, identify deviations earlier, and support predictive maintenance in GMP facilities. In commercialization, AI can improve demand planning during shortage conditions, align allocation with clinical priority, and analyze real-world evidence from electronic health records and registries while preserving compliance with privacy and pharmacovigilance requirements.

Key Regional Insights

Asia-Pacific represents a major long-term opportunity because China, India, Japan, South Korea, and Australia combine large aging populations with expanding urology infrastructure and growing oncology access. China and Japan are especially important due to high absolute bladder cancer burden and established hospital-based cancer care, while India is advancing access through broader oncology capacity and public health insurance expansion. South Korea and Australia add advanced diagnostic capacity, specialist urology networks, and strong regulatory expectations for quality and safety monitoring.

North America remains one of the most commercially advanced regions for therapeutic BCG vaccine adoption because the United States and Canada have strong guideline implementation, high cystoscopy utilization, mature reimbursement systems, and early uptake of therapies for BCG-unresponsive NMIBC. Europe benefits from harmonized clinical standards across major markets and broad access to specialist urologic oncology, although procurement, pricing, and national reimbursement pathways vary. Latin America, led by Brazil and Mexico, shows rising demand for intravesical immunotherapy but remains constrained by uneven access to specialist urology services, fragmented reimbursement, and regional disparities in cancer diagnosis. The Middle East, particularly GCC health systems, is investing in oncology infrastructure, tertiary hospitals, and centralized procurement, while Africa faces the greatest access challenges due to diagnostic limitations, constrained cold-chain capacity, later-stage cancer presentation, and lower availability of specialist bladder cancer care.

Key Group Insights

ASEAN markets present a practical growth corridor for therapeutic BCG vaccine manufacturers as cancer centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand diagnostic and urologic oncology services. Commercial success across ASEAN depends on cold-chain reliability, clinician education, hospital tender access, and public-private procurement models that support consistent product availability.

The GCC offers a high-investment healthcare environment where national cancer strategies, centralized procurement, tertiary hospitals, and growing medical tourism capacity can accelerate adoption of guideline-based NMIBC treatment. The European Union remains a highly regulated but attractive bloc due to clinical standardization, pharmacovigilance requirements, and biologics oversight under regional and national authorities. BRICS countries are strategically important because China, India, Brazil, Russia, and South Africa combine large patient pools with cost-sensitive access needs and increasing emphasis on domestic healthcare capacity. G7 and NATO-aligned markets generally offer strong regulatory predictability, mature pharmacovigilance expectations, established oncology infrastructure, and higher readiness for AI-supported evidence generation and supply-chain resilience.

Key Country Insights

The United States is the pivotal country market due to high guideline penetration, strong academic urology networks, broad cystoscopy access, and recognized regulatory pathways for BCG-unresponsive NMIBC alternatives. Canada follows similar clinical standards but with provincial reimbursement dynamics and centralized health technology assessment considerations. Mexico and Brazil offer growth potential driven by large populations and expanding cancer care, though access remains uneven across public and private systems and specialist availability varies by region.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have sophisticated urology systems and established intravesical therapy use, while Russia presents a sizable but more complex regulatory and procurement environment. China and India are central to future volume growth because of population scale, increasing bladder cancer detection, and expanding oncology infrastructure. Japan and South Korea are advanced, quality-sensitive markets with strong clinical adoption capacity, aging populations, and high expectations for post-treatment surveillance. Australia offers a smaller but well-regulated market with high standards for evidence, safety monitoring, and specialist care delivery.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing redundancy, validated strain control, and geographically diversified supply to reduce vulnerability to recurring BCG shortages. Companies should also invest in real-world evidence programs that measure recurrence-free survival, progression, adverse events, treatment completion, retreatment patterns, and outcomes after reduced-dose schedules.

Strategically, manufacturers should develop differentiated portfolios that include therapeutic BCG, recombinant or enhanced BCG candidates, and combination regimens for high-risk and BCG-unresponsive NMIBC. Partnerships with urology networks, cancer registries, contract manufacturers, and AI-enabled quality analytics vendors can improve evidence generation, access planning, pharmacovigilance, and operational resilience.

Research Methodology

This executive summary is built on secondary research from verified public-domain and regulatory sources, including IARC GLOBOCAN cancer statistics, WHO and national cancer resources, urology guideline bodies, regulatory approval databases, peer-reviewed oncology literature, and established clinical trial registries. The analysis emphasizes therapeutic BCG use in NMIBC and differentiates it from prophylactic tuberculosis vaccination.

Research inputs were triangulated across epidemiology, clinical guidelines, regulatory decisions, regional healthcare access indicators, biologics manufacturing considerations, and real-world evidence priorities. Insights were synthesized to support market interpretation while avoiding unsupported market-size claims, market-share estimates, or unverified projections.

Conclusion

Therapeutic BCG vaccine continues to occupy a critical position in bladder cancer care because it combines decades of clinical use with guideline-backed relevance in high-risk NMIBC. However, supply constraints, changing treatment algorithms, and rising expectations for BCG-unresponsive disease are redefining competitive advantage.

Manufacturers that combine robust biologics production, data-driven quality systems, clinical evidence generation, and regional access strategies will be best positioned to capture demand. The next phase of industry development will favor organizations that protect BCG availability while advancing more precise, tolerable, and durable intravesical immunotherapy solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Therapeutic BCG Vaccine Market, by Vaccine Type

  • 7.1. Standard BCG Vaccine
  • 7.2. Modified BCG Vaccines
  • 7.3. Next-Generation BCG-Based Immunotherapies

8. Therapeutic BCG Vaccine Market, by Indication

  • 8.1. Non-muscle Invasive Bladder Cancer
  • 8.2. Tuberculosis
  • 8.3. Autoimmune & Infectious Diseases

9. Therapeutic BCG Vaccine Market, by Route of Administration

  • 9.1. Intravesical Administration
  • 9.2. Intradermal Administration
  • 9.3. Intravenous

10. Therapeutic BCG Vaccine Market, by Treatment Regimen

  • 10.1. Induction Therapy
  • 10.2. Maintenance Therapy
  • 10.3. Combination Therapy Regimens

11. Therapeutic BCG Vaccine Market, by End User

  • 11.1. Hospitals
  • 11.2. Oncology Centers
  • 11.3. Specialty Clinics
  • 11.4. Research Institutes

12. Therapeutic BCG Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Therapeutic BCG Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Therapeutic BCG Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AJ Vaccines A/S
  • 16.2. Bharat Biotech International Limited
  • 16.3. Biofabri
  • 16.4. BioFarma
  • 16.5. Biological E. Limited
  • 16.6. Biomed Lublin S.A.
  • 16.7. Bul Bio-NCIPD Ltd.
  • 16.8. China National Biotec Group
  • 16.9. GlaxoSmithKline plc
  • 16.10. GreenSignal Bio Pharma Ltd.
  • 16.11. ImmunityBio, Inc.
  • 16.12. Indian Immunologicals Limited
  • 16.13. Instituto Butantan
  • 16.14. InterVax Ltd.
  • 16.15. Japan BCG Laboratory
  • 16.16. Laboratorios Reig Jofre S.A.
  • 16.17. Merck & Co., Inc.
  • 16.18. Microgen (NPO Microgen)
  • 16.19. Panacea Biotec Ltd.
  • 16.20. Sanofi
  • 16.21. Serum Institute of India Pvt. Ltd.
  • 16.22. Shanghai Institute of Biological Products Co., Ltd.
  • 16.23. Statens Serum Institut
  • 16.24. Taj Pharmaceuticals Limited
  • 16.25. Torlak Institute of Virology

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 104. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 122. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 128. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 141. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 147. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 153. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 165. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 177. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 189. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)